Two such corrector molecules (VX-661 and VX-445) are currently used in combination with an activating “potentiator” molecule (VX-770) in the drug cocktail Trikafta, which has been approved for the treatment of numerous patient genotypes.3,4 However, the underlying reasons why many clinical CF variants do not respond to these and other emerging CFTR modulators remain unknown. Here, CFTR is linked to cystic fibrosis.